Revive Therapeutics Ltd (RVVTF)

[Ice99]

Bucillamine went head to head with Colchicine with very favorable results in 2015 for a Phase 2a gout study. Bucillamine appeared to have less side effects and more importantly is a very strong Thiol donor which sets it apart.

Recent articles from the University of San Francisco study show that Bucillamine is one of the strongest Thiol donors. That alone sets it apart from Colchicine by giving it strong anti-inflammatory and Thiol donor capability.

See link to article which I posted earlier:

https://www.globenewswire.com/news-release/2015/12/01/1279498/0/en/Revive-Therapeutics-Announces-Positive-Final-Results-from-Its-Phase-2a-Study-for-the-Treatment-of-Acute-Gout-Flares.html